Uses
TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine (HY-B1046) [1][2][3].
References
[1] Xu J, et al. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02155-18. DOI:
10.1128/AAC.02155-18[2] Zhu H, et al. Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02164-20. DOI:
10.1128/AAC.02164-20[3] Ding Y, et al. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0065822. DOI:
10.1128/aac.00658-22
![2-Phenazinamine, 3,5-dihydro-3-[(4-methoxycyclohexyl)imino]-N-(2-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]- Structure](https://www.chemicalbook.com/CAS/20210305/GIF/1353734-12-9.gif)
